Intravacc’s Sabin Inactivated Polio vaccine (sIPV), outlicensed to LG Chem, receives WHO prequalification Bilthoven, the Netherlands, 21 January 2021 – Intravacc, a world leader in translational research and development of vaccines, today announces the WHO prequalification for the Sabin-IPV (sIPV)…

Intravacc’s Sabin Inactivated Polio vaccine (sIPV), outlicensed to LG Chem, receives WHO prequalification

• sIPV development is part of Intravacc’s contribution to the eradication of polio
• LG Chem is the first to receive WHO prequalification for the sIPV vaccine
• LG Chem signed an $80 million contract with UNICEF to supply polio vaccine starting early 2021

Intravacc announces completion of formulation and manufacturing process development of PRV-101 vaccine candidate for Provention Bio Bilthoven, the Netherlands, 19 January 2021 – Intravacc, a world leader in translational research and development of vaccines, today announced that a candidate polyvalent…

Intravacc announces completion of formulation and manufacturing process development of PRV-101 vaccine candidate for Provention Bio

• Potentially the first preventive vaccine for coxsackievirus B, a risk factor associated with type 1 diabetes and celiac disease
• First dosing of PRV-101 in the PROVENT Phase I clinical trial started in January 2021

Cristal Therapeutics and Intravacc Announce Strategic Collaboration to Advance Novel Vaccine Platforms Bilthoven and Maastricht, the Netherlands, 6 January 2021 – Intravacc, a world leader in translational research and development of vaccines, and Cristal Therapeutics,  a technology leader in enabling…

Cristal Therapeutics and Intravacc Announce Strategic Collaboration to Advance Novel Vaccine Platforms

• First joint CriVac® vaccine candidate to target receptor-binding domain of SARS-CoV-2
• Evaluation of Cristal’s CliCr® and Intravacc’s OMV technology

Intravacc appoints three Supervisory Board members Bilthoven, the Netherlands, 4 January 2021 – Intravacc, a world leader in translational research and development of vaccines, announces the appointment of three members in its Supervisory Board. As of January 1, 2021, Intravacc…

Intravacc appoints three Supervisory Board members

• Appointment of Nico Oudendijk (Chair), Bruno Bruins and Karin Dorrepaal
• Intravacc has become public shareholding company as per January 1, 2021

Dutch vaccine developer Intravacc becomes public shareholding company effective 1st January 2021 Bilthoven, The Netherlands, 22 December 2020 –  Intravacc, one of the leading translational research and development vaccine institutes with an extensive track record in developing infectious diseases vaccines,…

Dutch vaccine developer Intravacc becomes public shareholding company effective from 1st January 2021

• Dutch State will become sole shareholder
• Jan Groen will continue as Chief Executive Officer

Intravacc publishes positive phase I Shigella conjugate vaccine data Bilthoven, The Netherlands, 16 November 2020 –  Intravacc, one of the leading translational research and development vaccine institutes with an extensive track record in developing viral and bacterial vaccines, today announced…

Intravacc publishes positive phase I Shigella conjugate vaccine data

• High medical need for Shigella vaccine
• Over 250 million infections worldwide annually
• Vaccine was well tolerated and induced a significant increase in functional antibodies
• Data published in prestigious journal The Lancet Infectious Diseases